Newsroom | Gilead - Gilead Sciences
This is our global website, intended for visitors seeking information on Gilead’s worldwide business. Some content on this site is not intended for people outside the United States. Visit …
Gilead Sciences Announces Fourth Quarter and Full Year 2023 …
Feb 6, 2024 · FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2023. “This was …
Gilead Sciences
Gilead Sciences, a biopharma company, achieves bold ambitions to help make the world a healthier place, leading in HIV, liver disease, cancer & inflammation.
Gilead Sciences, Inc. - News
News: Quarterly Reports: SEC Filings: End of Day Stock Quote: Events & Presentations
Gileads Innovative HIV Treatment Research Pipeline ... - Gilead …
Mar 5, 2024 · “The latest findings across our HIV pipeline showcase the potential of multiple candidates to help transform HIV management,” said Jared Baeten, MD, PhD, Vice President, …
Gilead Sciences Announces Second Quarter 2024 Financial Results
Aug 8, 2024 · FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its second quarter 2024 results of operations. “Gilead has had another …
Gilead Sciences, Inc. - Gilead and Tubulis Enter Into Exclusive …
Dec 3, 2024 · – Single-Asset Focused Collaboration, License, and Option Agreement Combines Tubulis’ Differentiated ADC Platform Technologies with Gilead’s Oncology Research and …
News Details - Gilead Sciences
Feb 6, 2024 · “This was another strong year of revenue growth for Gilead’s base business, driven by both HIV and Oncology,” said Daniel O’Day, Gilead’s Chairman and Chief Executive …
Gilead Provides Update on Phase 3 EVOKE-01 Study - Gilead …
Jan 22, 2024 · FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of …
Gilead to Present Late Breaking Data and Real World ... - Gilead …
Feb 26, 2024 · FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new clinical data and real-world evidence …